Evaluation of in vivo gene mutation with etoposide using Pig-a and PIGRET assays

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 811, Issue , 2016, Pages 29-34

  Yamamoto, Mika ^a   Wakata, Akihiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Genotoxicity; In vivo mutation assay; Pig a gene

Indexed keywords

ETOPOSIDE; MEMBRANE PROTEIN; MUTAGENIC AGENT; PHOSPHATIDYLINOSITOL GLYCAN-CLASS A PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; BONE MARROW CELL; BONE MARROW SUPPRESSION; CELL MUTANT; CHROMOSOME ABERRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DNA CLEAVAGE; DOUBLE STRANDED DNA BREAK; DRUG MEGADOSE; ERYTHROCYTE; FLOW CYTOMETRY; GENE MUTATION; GENETIC ANALYSIS; GENOTOXICITY; IN VIVO STUDY; MALE; MICRONUCLEUS; NONHUMAN; PIG A ASSAY; PIGRET ASSAY; PRIORITY JOURNAL; RAT; RETICULOCYTE; ANIMAL; DRUG EFFECTS; EVALUATION STUDY; GENETICS; MUTAGEN TESTING; MUTATION; PROCEDURES;

ANIMALS; ERYTHROCYTES; ETOPOSIDE; MEMBRANE PROTEINS; MUTAGENICITY TESTS; MUTAGENS; MUTATION; RATS; RETICULOCYTES;

EID: 84978805174     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2016.06.006     Document Type: Article

References (30)

1. [1] Kimoto, T., Suzuki, K., Kobayashi, X., Dobrovolsky, V.N., Heflich, R.H., Miura, D., Kasahara, Y., Manifestation of Pig-a mutant bone marrow erythroids and peripheral blood erythrocytes in mice treated with N-ethyl-N-nitrosourea: direct sequencing of Pig-a cDNA from bone marrow cells negative for GPI-anchored protein expression. Mutat. Res. 723 (2011), 36–42.
2. [2] Miura, D., Dobrovolsky, V.N., Kimoto, T., Kasahara, Y., Heflich, R.H., Accumulation and persistence of Pig-A mutant peripheral red blood cells following treatment of rats with single doses of N-ethyl-N-nitrosourea. Mutat. Res. 677 (2009), 86–92.
3. [3] Kimoto, T., Chikura, S., Suzuki, K., Kobayashi, X., Itano, Y., Miura, D., Kasahara, Y., Effective use of the Pig-a gene mutation assay for mutagenicity screening: measuring CD59-deficient red blood cells in rats treated with genotoxic chemicals. J. Toxicol. Sci. 37 (2012), 943–955.
4. [4] Gollapudi, B.B., Lynch, A.M., Heflich, R.H., Dertinger, S.D., Dobrovolsky, V.N., Froetschl, R., Horibata, K., Kenyon, M.O., Kimoto, T., Lovell, D.P., Stankowski, L.F. Jr., White, P.A., Witt, K.L., Tanir, J.Y., The in vivo Pig-a assay: a report of the International Workshop on Genotoxicity Testing (IWGT) Workgroup. Mutat. Res. 783 (2015), 23–35.
5. [5] Phonethepswath, S., Franklin, D., Torous, D.K., Bryce, S.M., Bemis, J.C., Raja, S., Avlasevich, S., Weller, P., Hyrien, O., Paris, J., MacGregor, J.T., Dertinger, S.D., Pig-a mutation: kinetics in rat erythrocytes following exposure to five prototypical mutagens. Toxicol. Sci. 114 (2010), 59–70.
6. [6] Dertinger, S.D., Phonethepswath, S., Avlasevich, S.L., Torous, D.K., Mereness, J., Bryce, S.M., Bemis, J.C., Bell, S., Weller, P., MacGregor, J.T., Efficient monitoring of in vivo Pig-a gene mutation and chromosomal damage: summary of 7 published studies and results from 11 new reference compounds. Toxicol. Sci. 130 (2012), 328–348.
7. [7] Kimoto, T., Chikura, S., Suzuki, K., Kobayashi, X., Itano, Y., Horibata, K., Honma, M., Dobrovolsky, V.N., Heflich, R.H., Miura, D., Kasahara, Y., Further development of the rat Pig-a mutation assay: measuring rat Pig-a mutant bone marrow erythroids and a high throughput assay for mutant peripheral blood reticulocytes. Environ. Mol. Mutagen 52 (2011), 774–783.
8. [8] ICH harmonized tripartite guideline, Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7 Current Step 4 version dated 23 (2014).
9. [9] Itoh, S., Nagata, M., Hattori, C., Takasaki, W., In vivo mutagenicity of ethyl methanesulfonate detected by Pig-a and PIGRET assays. Genes Environ. 36 (2014), 174–178.
10. [10] Sanada, H., Okamoto, M., Ohsumi, T., Nakamura, T., Evaluation for a mutagenicity of 4,4′-methylenedianiline on hematopoietic cells by a Pig-a gene mutation assay in rats. Genes Environ. 36 (2014), 179–185.
11. [11] Muto, S., Yamada, K., Kato, T., Iwase, Y., Uno, Y., Pig-a gene mutation and micronucleus induction in rat peripheral blood by methyl methanesulfonate. Genes Environ. 36 (2014), 186–190.
12. [12] Kimoto, T., Chikura, S., Okada, K.S., Kobayashi, X., Itano, Y., Miura, D., Kasahara, Y., The rat Pig-a mutation assay in single and 28 day-repeated dose study of cyclophosphamide: the PIGRET assay can detect the in vivo mutagenicity earlier than the RBC Pig-a assay. Genes Environ. 36 (2014), 191–198.
13. [13] Horibata, K., Ukai, A., Honma, M., Evaluation of rats in vivo genotoxicity induced by N-ethyl-N-nitrosourea in the RBC Pig-a, PIGRET, and gpt assays. Genes Environ. 36 (2014), 199–202.
14. [14] Kimoto, T., et al. The PIGRET assay, a method for measuring Pig-a gene mutation in reticulocytes, is reliable as a short-term in vivo genotoxicity test: summary of the MMS/JEMS-collaborative study across 16 laboratoriesusing 24 chemicals. Mutat. Res. 811 (2016), 3–15.
15. [15] Sakamoto, M., et al. Safety studies of etoposide (NK171) (first report). Clin. Rep. 19:8 (1985), 7–36.
16. [16] Kimoto, T., Horibata, K., Chikura, S., Hashimoto, K., Itoh, S., Sanada, H., Muto, S., Uno, Y., Yamada, M., Honma, M., Interlaboratory trial of the rat Pig-a mutation assay using an erythroid marker HIS49 antibody. Mutat. Res. 755 (2013), 126–134.
17. [17] van Maanen, J.M.S., Lafleur, M.V., Mans, D.R., van den Akker, E., De Ruiter, C., Kootstra, P.R., Rappie, D., de-Vries, J., Retel, J., Pinedo, H.M., Effects of the ortho-quinone and catechol of the antitumor drug VP-16-213 on the biological activity of single-stranded and double-stranded phi X174 DNA. Biochem. Pharmacol. 37 (1988), 3579–3589.
18. [18] Maede, Y., Shimizu, H., Fukushima, T., Kogame, T., Nakamura, T., Miki, T., Takeda, S., Pommier, Y., Murai, J., Differential and common DNA repair pathways for topoisomerase I and II-targeted drugs in a genetic DT40 repair cell screen panel. Mol. Cancer Ther. 13:1 (2014), 214–220.
19. [19] Ezoe, S., Secondary leukemia associated with the anti-cancer agents etoposide, a topoisomerase II inhibitor. Int. J. Environ. Res. Public Health 9 (2012), 2444–2453.
20. [20] IARC, IARC, Monographs on the Evaluation of the Carcinogenic Risks to Humans, Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents vol. 76 (1999) 177–257.
21. [21] Mahgoub, N., Taylor, B.R., Le Beau, M.M., Gratiot, M., Carlson, K.M., Atwater, S.K., Jacks, T., Shannon, K.M., Myeloid malignancies induced by alkylating agents in Nf1 mice. Blood 93 (1999), 3617–3623.
22. [22] Ashby, J., Tinwell, H., Glover, P., Poorman-Allen, P., Krehl, R., Callander, R.D., Clive, D., Potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells. Environ. Mol. Mutagen. 24 (1994), 51–60.
23. [23] Nakanomyo, H., Hiraoka, M., Shiraya, M., Mutagenicity tests of etoposide and teniposide. J. Toxicol. Sci. 11 (1986), 301–310 (in Japanese).
24. [24] Gupta, R.S., Bromke, A., Bryant, D.W., Gupta, R., Slingh, B., McCalla, D.R., Etoposide (VP16) and teniposide (VM26): novel anticancer drugs strongly mutagenic in mammalian but not prokaryotic test systems. Mutagenesis 2 (1987), 179–186.
25. [25] Matney, T.S., Nguyen, T.V., Connor, T.H., Theiss, J.C., Dana, W.J., Genotoxic classification of anticancer drugs. Teratg. Carcinog. Mutagen. 5 (1985), 319–328.
26. [26] Suzuki, H., Nakane, S., Differential induction of chromosomal aberrations by topoisomerase inhibitors in cultured chinese hamster cells. Biol. Pharm. Bull. 17 (1994), 222–226.
27. [27] Chen, C.L., Woo, M.H., Neale, G.A.M., Goorha, R.M., Fuscoe, J.C., Behm, F.G., Mathew, S., Relling, M.V., A humanlymphoid leukemia cell line with a V(D)J recombinase-mediated deletion of hprt. Mutat. Res. 403 (1998), 113–125.
28. ® method for the flow cytometric analysis of micronuclei in rat bone marrow erythrocytes. Mutat. Res. 703 (2010), 122–129.
29. +/− mice. Environ. Mol. Mutagen. 39 (2002), 342–347.
30. [30] Tinwell, H., Lefevre, P.A., Ashby, J., Relative activities of methyl methanesulfonate (MMS) as a genotoxin, clastogen and gene mutagen to the liver and bone marrow of MutaTM mouse mice. Environ. Mol. Mutagen. 32 (1998), 163–172.